Science & Programs
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.
Apabetalone
The world leader in a new class of drugs designed to regulate disease-associated epigenetics.
Learn More
Clinical Trials
BETonMACE – a global Phase 3 clinical trial with the most advanced epigenetic drug outside of oncology.
Learn More
Partnership Strategy
Providing novel science, clinical and value-based health solutions to key stakeholders, including payer groups.
Learn More
Investors
Resverlogix (TSX: RVX), founded in 2001 by Donald McCaffrey and Norman Wong, focuses on the development of therapeutics for disease states with high unmet medical need.
News Releases
View All
Financial Reports
View All
Presentations & Events
View All